In reference to your comment: "nows this companies time"...if you read the last 10Q (for new newbies), specifically: In June 2015 we received a sample of the scale-up manufacturing process for evaluation and confirmation of adherence to specifications. Based upon our laboratory analyses, the sample meets all of the required chemical, physical and biological specifications. This paves the way for moving forward with large scale manufacturing of a 2-kilogram quantity for the IND-Enabling studies and clinical trials. If the timetable for generating the 2-kilogram quantity is met, of which there can be no assurance, and subject to receipt of the necessary financing, also for which no assurances can be provided, we expect to move into Phase I of our clinical trials in late 2016 or early 2017.
And:
Adva-27a's initial indication will be pancreatic cancer and multidrug resistant breast cancer for which there are currently little or no treatment options available. In June 2011 we concluded an agreement with McGill University's Jewish General Hospital in Montreal, Canada to conduct Phase I clinical trials for these two indications. All aspects of the planned clinical trials in Canada will employ U.S. Food and Drug Administration ("FDA") standards at all levels. If adequate funding is obtained, of which there is no assurance, we now anticipate that Phase I clinical trials will commence in late 2016 or early 2017 and we estimate that it will take 18 months to complete, at which time we expect to receive limited marketing approval for "compassionate-use" under the FDA and similar guidelines in Canada.
Not to be a bigger buzz kill than buzz killington, but where is your information coming from, that suggests "any day, soon, coming"? Their own 10Q filing gives tentative dates, with no assurances (end of 2016 into 2017) maybe......I'm rooting for this stock, but I'm also practical. I hope they release an up to date 10Q with better timelines...
I also have some reservations about the connection between Advanomics and Sunshine. Same owner, but transactions between the two companies. I'd personally love to see Sunshine run by an independent CEO, alleviate conflicts of interest. Just my two cents...for new readers, or investors thinking about this stock
